Welcome to Clinuvel

We are a global biopharmaceutical company committed to developing drugs for the treatment of a range of severe skin disorders.

Clinuvel’s lead compound, SCENESSE® (afamelanotide), a first-in-class drug targeting erythropoietic protoporphyria (EPP), has completed Phase II and III trials in the US and Europe. In February 2012 SCENESSE® was filed for review by the European Medicines Agency for EPP. Further trials of SCENESSE® are underway in the pigmentary disorder vitiligo.

Our website has been developed to help share our expertise on the interaction of light and human skin as well as provide a thorough overview of our global drug development programs.

Clinuvel Latest News

Clinuvel files European MAA for SCENESSE® (afamelanotide)

Clinuvel has filed a marketing authorisation application (MAA) with the European Medicines Agency (EMA) for the orphan disease erythropoietic protoporphyria (EPP). To read the company's full announcement, click here. Read a blog post from Clinuvel's CEO, Dr Philippe Wolgen, on the MAA filing: MAA: a moment in Clinuvel's EPP story Media coverage: Australian Life Sci...

Read more

Vitiligo Latest News

First positive observations from Clinuvel’s US vitiligo trial

In October 2011 early clinical observations from the company’s open label Phase II pilot trial (CUV102) of the novel drug SCENESSE® (afamelanotide) in patients with nonsegmental vitiligo (NSV) were presented at the European Academy of Dermatology and Venereology (EADV) meeting in Lisbon. You can read the full announcement here....

Read more

Clinuvel Stock Ticker

Press Coverage

Clinuvel Blog Posts

Delivering a therapy for those who need it most: EPP...

Earlier today we announced that two health insurers in Switzerland had agreed to reimburse SCENESSE® (afamelanotide) for the rare disease...

Read More

New UK coins may pose skin allergy risk...

In a letter published this week in the British Journal of Medicine three dermatologists have highlighted the potential risks posed by the...

Read More

Living with HV...

In the final post from the Roosenboom family, and to help recognise Rare Diseases Day, Simone has penned her own piece on her experiences...

Read More

Clinuvel Webcasts

Understanding Vitiligo: Misconception & Myth...

Vitiligo is a skin disorder which causes the loss of pigment - melanin - in the skin. Though it affects around 45 million people worldwide,...

Watch now

'Check up' reports on rare disease EPP and SCENESSE...

On 31 January 2012 Swiss TV channel Telezueri aired a report on erythropoietic protoporphyria (EPP), a rare genetic disorder which causes ab...

Watch now

"Focus really pays off in the end"...

Following Clinuvel's landmark filing of a marketing authorisation application for the drug SCENESSE® (afamelanotide) with the European Medic...

Watch now

Clinuvel Spotlight

Company History

The technology behind Clinuvel’s lead drug, SCENESSE® (afamelanotide), has been in research and development since the 1980s when a small team of scientists set out to investigate methods of preventing skin cancer in humans. Clinuvel licensed this technology and has spent over A$20million optimising the chemistry of afamelanotide (the active ingredient in SCENESSE®) an...

Read more